capmatinib

Overview

Capmatinib is a selective, potent MET inhibitor FDA-approved for MET exon 14 skipping mutation-positive non-small cell lung cancer. It retains activity against several MET resistance mutations that arise on first-generation inhibitors.

Evidence in the corpus

• A patient with MET exon 14 skipping-positive lung cancer and CNS metastases was transitioned from crizotinib to capmatinib after CSF ctDNA profiling detected the MET p.Y1230N resistance mutation. Serial CSF ctDNA monitoring showed response to capmatinib with clearance of the resistance clone PMID:39289779.
• CSF ctDNA sequencing enabled real-time monitoring of treatment response to capmatinib in the CNS compartment, illustrating the clinical utility of liquid biopsy for guiding MET-directed therapy PMID:39289779.
• Cited as a selective MET inhibitor under evaluation in HCC; MET overexpression associated with poor prognosis and sorafenib resistance PMID:24798001
• MET exon 14 skipping inhibitor; pivotal trial enrolled patients up to 74 years old; MET exon 14 skipping rare in young-onset NSCLC (<40 years) at 0.72% versus 3.25% in patients >70 years PMID:27346245

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• NSCLC
• LUAD

Sources

• PMID:39289779

This page was processed by crosslinker on 2026-05-04. - PMID:24798001

This page was processed by wiki-cli on 2026-05-11. - PMID:27346245

This page was processed by wiki-cli on 2026-05-14.